This study is being conducted to evaluate the effectiveness and safety of a medication called NNC0487-0111, which contains the active substance zenagamtide. The research focuses on individuals living with overweight or obesity, which refers to having excess body weight, and knee osteoarthritis, a condition involving the wear and tear of the joints in the knee that can cause discomfort. The investigation aims to determine if the study drug can assist in weight reduction and the management of joint-related pain.

Participants in the study will receive either the test medication or a placebo. The medication is administered through a subcutaneous injection, which means it is delivered into the fatty layer of tissue just under the skin, using a pre-filled pen once per week. During the study, changes in body weight, waist size, and various health measurements will be monitored. Additionally, the impact on knee pain, stiffness, and physical movement will be observed to see how the treatment affects daily function.